Recent developments in chemotherapy of advanced gastric cancer

Digestive Diseases

Volumn 22, Issue 4, 2004, Pages 360-365

  Götze, Tobias ^a   Schütte, Kerstin ^a   Röcken, Christoph ^a   Malfertheiner, Peter ^a   Ebert, Matthias P A ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Capecitabine; Gastric cancer; Gastric cancer, palliative treatment; Irinotecan; Oxaliplatin; Taxane

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; UFT; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL DIVISION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS CARCINOMA; HUMAN; JAPAN; METASTASIS; NAUSEA; NEUTROPENIA; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TIME; TOXICITY; CANCER STAGING; PATHOLOGY; STOMACH TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM STAGING; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 21844431673     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083599     Document Type: Review

References (35)

1. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
2. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
3. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648-2657.
4. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat 1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
5. Koizumi W, Kurihara M, Nakano S, Hasegawa K, The S1 Cooperative Gastric Cancer Study Group: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-197.
6. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-2212.
7. Takiuchi H, Ajani JA: Uracil-tegafur in gastric carcinoma: A comprehensive review. J Clin Oncol 1998;16:2877-2885.
8. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002;13:1893-1898.
9. De Lange SM, van Groeningen CJ, Kroep JR, Van Bochove A, Snijders JF, Peters GJ, Pinedo HM, Giaccone G: Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann Oncol 2004;15:484-488.
10. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;15:658-663.
11. Cocconi G, Carlini P, Gamboni A, et al: PELF is more active than FAMTX in metastatic gastric carcinoma. Proc Am Soc Clin Oncol 2001;20:A501.
12. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS: Paclitaxel, 5- Fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999;85:295-301.
13. Chun H, Olson C, Mittelman A, Puccio C, Kang M, Ahmed T: Chemotherapy with cisplatin, fluorouracil and paclitaxel for adenocarcinoma of the stomach and gastrooesophageal junction. Proc Am Soc Clin Oncol 1999;18:A280.
14. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L: A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000;83:458-462.
15. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A: Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-306.
16. Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner MM, Goldhirsch A, de Braud F: 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: A phase I-II trial. Ann Oncol 2004;15:759-764.
17. Ajani J, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zuber E, Blattmann: Doxetaxel, cisplatin, 5-fluorouracil for chemonaive patients with metastasic or locally recurrent, unresectable gastric carcinoma: Interim results of a randomized phase III trial. Proc Am Soc Clin Oncol 2003;22:A258.
18. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, Eichelmann K, Lippert H: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-51.
19. Lee SH, Kang WK, Park J, Kim HY, Kim JH, Lee SI, Park JO, Kim K, Jung CW, Park YS, Im YH, Lee MH, Park K: Combination chemotherapy with epirubicin, docetaxel and cisplatin in metastatic or recurrent, unresectable gastric cancer. Br J Cancer 2004;91:18-22.
20. Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S, Souglakos J, Sarra E, Vardakis N, Hatzidaki D, Sarmonis G, Georgoulias V: Front-line treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor: A phase II trial. Am J Clin Oncol 2000;23:341-344.
21. Park YH, Ryoo BY, Choi SJ, Kim HT: A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004;90:1329-1333.
22. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
23. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM: Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 2004;34:8-13.
24. Bugat R: Irinotecan in the treatment of gastric cancer. Ann Oncol 2003;14(suppl 2):37-40.
25. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004;15:64-69.
26. Kohne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ: Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentrictrial. Br J Cancer 2003;89:997-1001.
27. Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis C, Vardakis N, Christophilakis C, Kotsakis A, Georgoulias V: Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: A multicentre phase II trial. Ann Oncol 2004;15:1204-1209.
28. Bouche O, Raoul JL, Giovanini M, Etienne PL, Bedenne L, Lledo G, Arsene D, Paitel JF, Seitz JF, Milan C: Randomized phase II trial of LV 5FU2,LV 5FU2-cisplatinum or LV 5FU2-irinotecan in patients with metastatic gastric or cardial adenocarcinoma: Final results of study FFCF 9803. Proc Am Soc Clin Oncol 2003;22:A1033.
29. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer 2002;94:641-646.
30. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-323.
31. Pozzo C, Peschel C, Gorbunova V, Valvere V, Zalusky J, Biakhov M: Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: Final results of a randomized phase II study. Proc Am Soc Clin Oncol 2001;20:A531.
32. Moehler M, Hoehler T, Siebler J, Jansen J, Wein A, Menges M, Flieger D, Geer T, Galle P, Heike M: Safety and efficacy of CPT11/FA/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction. Proc Am Soc Clin Oncol.2003;22:A258.
33. Hoehler T, Moehler M: Neue Chemotherapeutika in der Therapie des fortgeschrittenem oder metastasierten Magenkarzinoms. Onkologie 2003;26:54-59.
34. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548.
35. Murad AM, Garcia RF, Vinholes J, et al: A phase II multicentric trial of docetaxel (Taxotere), 5-fluorouracil and epirubicin in previously untreated advanced gastric cancer: a novel and effective regimen. Proc Eur Soc Med Oncol 2002, abstr 710.